Trial Profile
An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; VXM-01 (Primary) ; Ascorbic acid; Lactose; Sodium bicarbonate
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors VAXIMM
- 19 Oct 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 19 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Jun 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.